Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
06:47pm, Monday, 06'th May 2024
The company unveiled its first-quarter earnings that morning. It notched convincing beats on both the top and bottom lines.
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript
11:42am, Monday, 06'th May 2024
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2024 Earnings Call Transcript May 6, 2024 8:30 AM ET Company Participants John Bluth - IR Jon Stonehouse - CEO Charlie Gayer - CCO Helen Thackray - Chi
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
09:11am, Monday, 06'th May 2024
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.28 per share a year ago.
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Monday, 06'th May 2024
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline p
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 03'rd May 2024
RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Monday, 29'th Apr 2024
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Report First Quarter 2024 Financial Results on May 6
07:00am, Monday, 22'nd Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
04:30am, Wednesday, 17'th Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approva
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 03'rd Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Monday, 25'th Mar 2024
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmu
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Tuesday, 05'th Mar 2024
RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
08:29am, Friday, 01'st Mar 2024
Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more.
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript
11:29am, Monday, 26'th Feb 2024
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
09:11am, Monday, 26'th Feb 2024
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.38 per share a year ago.
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
07:00am, Monday, 26'th Feb 2024
—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) —
